Latest Breaking News On - Davidr spigel - Page 1 : comparemela.com

Osimertinib delays progression way more than hoped in EGFR -mutant lung cancer

CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.Blinded independent review and study investigators separately determined a greater than 80% risk reduction for those treated with the osimertinib-based regimen, according to results presented at ASCO

United statesJosh friedmanSureshs ramalingamMindy valcarcelOsimertinib tagrissoJulier gralowDavidr spigelByjosh friedmanWinship cancer institute of emory universitySarah cannon research instituteWinship cancer instituteEmory university

AstraZeneca s Tagrisso greatly slows cancer for some people with stage 3 lung cancer

AstraZeneca s Tagrisso greatly slows cancer for some people with stage 3 lung cancer
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Astrazeneca tagrissoDavidr spigel

Osimertinib Offers 84% Improvement in PFS Over Standard of Care in Stage III Unresectable EGFR-Driven NSCLC

A pair of late-breaking trials, LAURA and ADRIATIC, promise practice-changing news in lung cancer.

United statesLauren byersSureshs ramalinganDavidr spigelWinship cancer institute of emory universityMd anderson cancer centerAmerican society of clinical oncologySarah cannon research instituteAmerican societyClinical oncologyWinship cancer instituteEmory universityNew england journalAmerican journalNeck medical oncologyCancer center

Lorlatinib produces unprecedented disease progression delay in ALK -positive lung cancer

CHICAGO — Lorlatinib delivered never-before-seen PFS results in adults with anaplastic lymphoma kinase-positive non-small cell lung cancer, according to findings from a randomized phase 3 trial presented at ASCO Annual Meeting.Lorlatinib (Lorbrena, Pfizer) also drastically delayed disease progression and development of brain metastases compared with crizotinib (Xalkori, Pfizer).

United statesLorlatinib lorbrenaMindy valcarcelJulier gralowDavidr spigelByjosh friedmanPeter maccallum cancer centerSarah cannon research institute

Outstanding 5 Year PFS With Lorlatinib in ALK+ NSCLC

Five-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.

United statesJessicaj linDavidr spigelEuropean society for medical oncology virtual congressPeter maccallum cancer centreSarah cannon research instituteAmerican society of clinical oncologyHarvard medical schoolDrug administrationBenjamin solomonClinical oncologyLung medical oncologyMedscape medical newsMedical oncology virtual congressThoracic cancersMassachusetts general hospital